- ROUNDTABLE: Pharmacy’s future in sync with technology
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
- Study from NCPA sheds new light on med synchronization programs
- Senate passes Drug Quality and Security Act
- Diplomat's Jennifer Hagerman named president-elect of Michigan Pharmacists Association for 2014
FLINT, Mich. – A webinar next week about specialty drugs expected to enter the U.S. marketplace over the next 12 months and strategies that can improve patient outcomes while keeping costs down will include a speaker from one of the country's biggest specialty pharmacies.
Diplomat Specialty Pharmacy SVP sales and business development Atheer Kaddis will appear in the Sept. 12 webinar, Payer Tactics to Manage High-Cost Specialty Drugs in the Pipeline, for which Atlantic Information Services will serve as host. Diplomat is the largest independent, privately owned specialty pharmacy in the country and experienced 199% growth in sales between 2009 and 2012, recently landing on Inc. magazine's list of the top-5,000 fastest-growing private companies.
"Specialty drugs are expected to contribute to approximately half of all pharmacy spend over the next five years," said Kaddis, who has worked as an executive at Diplomat since 2007. "That kind of rapid expansion means payers need to understand where to focus their attention and resources so that they can best position themselves for better management of these new therapies."